TPO inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of Thyroid Peroxidase (TPO), an essential enzyme involved in the synthesis of thyroid hormones. TPO is a heme-containing enzyme located in the thyroid gland's follicular cells and plays a critical role in catalyzing the iodination of tyrosine residues in thyroglobulin, a precursor protein, and the subsequent coupling of iodotyrosines to form the active thyroid hormones, thyroxine (T4) and triiodothyronine (T3). These hormones are crucial for regulating metabolism, growth, and development in various tissues throughout the body. By inhibiting TPO, researchers can disrupt the synthesis of thyroid hormones, offering a valuable tool for studying the biochemical pathways underlying thyroid hormone production and its regulation.
In research settings, TPO inhibitors are instrumental in exploring the molecular mechanisms that control thyroid hormone biosynthesis and the broader implications of thyroid hormone regulation on metabolic processes. By blocking TPO activity, scientists can investigate how the inhibition affects the various steps in the thyroid hormone synthesis pathway, including iodide oxidation, iodination of tyrosine residues, and the coupling reactions that lead to hormone formation. This inhibition allows researchers to study the downstream effects of reduced thyroid hormone levels on cellular metabolism, gene expression, and physiological processes in target tissues. Additionally, TPO inhibitors provide insights into the regulatory networks that control TPO activity and thyroid hormone synthesis, such as the role of iodine availability, feedback mechanisms, and interactions with other enzymes involved in thyroid function. Through these studies, the use of TPO inhibitors enhances our understanding of the biochemical and physiological processes underlying thyroid hormone production, the regulation of metabolic activity, and the broader impact of thyroid function on overall health and development.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Eltrombopag | 496775-61-2 | sc-207614 sc-207614A sc-207614B | 5 mg 50 mg 100 mg | $263.00 $381.00 $490.00 | 1 | |
Small molecule TPO receptor agonist, indirectly influences TPO activity. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Reduces platelet production, potentially affecting TPO-related pathways. | ||||||
Danazol | 17230-88-5 | sc-203021 sc-203021A | 100 mg 250 mg | $92.00 $238.00 | 3 | |
Alters levels of growth factors affecting blood cells, potentially impacting TPO activity. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $37.00 $109.00 | 1 | |
Immunosuppressant, can affect bone marrow and thus indirectly influence TPO activity. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Alkylating agent, impacts bone marrow, potentially affecting TPO pathways. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Immunosuppressive drug, may influence hematopoiesis and indirectly TPO activity. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Antineoplastic drug, affects bone marrow function, potentially impacting TPO. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates immune response and angiogenesis, potentially affecting TPO pathways. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Immunomodulatory drug, affects bone marrow microenvironment, potentially influencing TPO. | ||||||
Busulfan | 55-98-1 | sc-204658 | 10 g | $49.00 | 3 | |
Alkylating agent, affects hematopoiesis, potentially impacting TPO activity. | ||||||